Literature DB >> 24716863

Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study.

Nozomi Iwanaga1,2, Kazuhiko Arima3, Kaoru Terada1, Yukitaka Ueki1, Yoshiro Horai4, Takahisa Suzuki4, Yoshikazu Nakashima4, Shin-Ya Kawashiri3, Kunihiro Ichinose4, Mami Tamai4, Hideki Nakamura4, Kiyoshi Aoyagi3, Atsushi Kawakami4, Tomoki Origuchi4,5.   

Abstract

OBJECTIVES: The risk factors of adverse events during a number of currently used treatments for rheumatoid arthritis (RA) in elderly patients were examined.
METHODS: A retrospective observational study was conducted for 300 elderly RA patients registered in December 2009 at Sasebo Chuo Hospital, Japan, and the adverse events during the treatments for RA were assessed.
RESULTS: The average age of the patients was 74.3 ± 5.8 years. The Steinbrocker stage was IV in almost one-half of the patients. Methotrexate (MTX) was used in 54.0% of patients and biologics in 23.0% of patients. Adverse events occurred in 103 patients (34.3%). The most common adverse events were infections (46.6%), including pneumonia (21.4%). Multiple logistic analyses revealed that the factors significantly related to infection were advanced Steinbrocker stage and the existence of respiratory diseases, and that of pneumonia was the existence of diabetes mellitus (DM).
CONCLUSIONS: The elderly RA patients with advanced stage, respiratory diseases or DM should be monitored for infections, including pneumonia, carefully during treatment.
© 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  adverse event; drug treatment; rheumatoid arthritis

Mesh:

Substances:

Year:  2014        PMID: 24716863     DOI: 10.1111/1756-185X.12348

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  5 in total

Review 1.  Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.

Authors:  Susan M Goodman
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

Review 2.  Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.

Authors:  Alla Ishchenko; Rik J Lories
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

3.  Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study.

Authors:  Klara Morsley; Thomas Kilner; Alan Steuer
Journal:  Rheumatol Ther       Date:  2015-11-25

Review 4.  Management of inflammatory rheumatic conditions in the elderly.

Authors:  Clément Lahaye; Zuzana Tatar; Jean-Jacques Dubost; Anne Tournadre; Martin Soubrier
Journal:  Rheumatology (Oxford)       Date:  2019-05-01       Impact factor: 7.580

5.  Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register.

Authors:  Paloma Vela; Carlos Sanchez-Piedra; Carolina Perez-Garcia; María C Castro-Villegas; Mercedes Freire; Lourdes Mateo; Cesar Díaz-Torné; Cristina Bohorquez; Juan M Blanco-Madrigal; Inmaculada Ros-Vilamajo; Silvia Gómez; Rocio Caño; Fernando Sánchez-Alonso; Federico Díaz-González; Juan J Gómez-Reino
Journal:  Arthritis Res Ther       Date:  2020-06-15       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.